LeonaBio Inc
leonabio.comWhat Do They Do?
Develops drug candidates for patients with treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$19MView ↗
- ▲ +173% (Loss)
- vs −$7M in Q2 FY2025
A shift toward breast cancer
The older report focused on neurological disease candidates, including one for Alzheimer’s and Parkinson’s-related dementia. The latest report adds a breast cancer candidate alongside its ALS candidate.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 31, 2026We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs…View ↗
Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene…View ↗
Figure 1 below illustrates the current development stage of our proprietary drug candidates and early discovery and development programs…View ↗
Who Do They Compete With?
Competes with The Menarini Group, Eli Lilly, AstraZeneca, Arvinas, Olema, F. Hoffman- La Roche, Helixmith, and Kringle Pharma
10-K for FY2025, filed Mar 31, 2026While lasofoxifene is a novel SERM, several pharmaceutical and biotechnology companies are developing or marketing 1L+ therapies for…View ↗
Loading...
